Head of the Laboratory
Furio Gramatica, physicist, was born in Milano in 1964. He is the Chair of the Centre for Innovation and Technology Transfer (CITT) at Don Gnocchi Foundation – an Italian chain of 29 healthcare and research centres specialized in rehabilitation – where he also leads the Nanomedicine and Clinical Biophotonics Laboratory (LABION).
For five years he served as Director of the Biomedical Technology Department “Polo Tecnologico” in the same Foundation. Formerly, he spent several years at CERN (Geneva), at Italian Institute of Nuclear Physics and in high-technology companies, with R&D management roles. Dr. Gramatica is fellow professor of physics at Milan University Medical School, Chair of the Working Group Clinical Interface, Executive Board Member of the European Technology Platform of Nanomedicine, evaluator and reviewer of the European Commission and of Wellcome Trust.
Marzia Bedoni received her MSc degree in Biological Sciences in 2004 and her PhD degree in Morphological Science in 2007 (University of Milan). From 2007 to 2010 she carried out her Post-Doctorate at LABION of the Don Gnocchi Foundation granted by the Cariplo Foundation, Seed Capital and Seventh Framework Programme. From January 2011 she is permanent researcher in FDG. Her research activity is mainly addressed to: salivary biomarker discovery for neurodegenerative diseases by mass-spectrometry, biophotonics application for early diagnosis and therapy monitoring in skin diseases (psoriasis, cancer), leukemia and neurodegenerative diseases, nanoparticles toxicity on human skin biology, biocompatibility in transdermal drug delivery and dry electrodes devices. From 2007 she is also lecturer in Human Anatomy for the Faculty of Medicine and Surgery at the University of Milan.
She received some awards during international congresses for her research studies. She is author of 25 papers published in peer-reviewed scientific journals, several abstracts for national and international congresses and she is also co-inventor of 4 patents.
She is board member of the “Society for Cutaneous Ultrastructure Research (SCUR)”, and ordinary member of the “European Society of Dermatological Research” and the “Italian Society of Human Anatomy”. She is involved in several national and international projects.
Carlo Morasso joined LABION in 2011 after a period as post doctoral scientist at London Centre for Nanotechnology – UCL under the supervision of Dr. Rachel McKendry. Graduated in pharmaceutical chemistry and technologies (CTF) at the University of Milan he got his PhD in medicinal chemistry at the same institution in 2008. Expert in nanotechnology and optical spectroscopies (Raman, DLS, UV Vis), his research activity is focused on the implementation of biosensing techniques and, in particular, on the use of plasmonic based systems, as new diagnostic tools for cancer and neurodegenerative diseases.
Carlo is author of several articles and book chapters on biomedical applications of nanotechnology and is a reviewer for several journals in the field as Chem. Comm., Analyst and RSC Advances. Currently, Carlo is project coorodinator of InNaSERSS a 800 k€ Euronanomed II – FP7 project, involving 4 partners form 3 European countries, focused on the design of a SERS based diagnostic platform for the ultra sensible detection of genetic biomarkers. Carlo is a member of the Royal Society of Chemistry.
Renzo Vanna received his Master’s degree in Biotechnology from University of Pavia in 2008. He received his PhD degree in Molecular Medicine at University of Milan and CNR-ITB (2011), focusing his research on brain aging and neurodegeneration by a proteomic approach. He joined FDG as young researcher starting to collaborate in a project aimed at the development of a new SERS-based biosensor for gene expression for the evaluation of minimal residual disease in acute myeloid leukemia (AML). During this period he spent a period of six months working as visiting scientist at University of Twente, The Netherlands, under the supervision of Dr. Cees Otto and Prof. Leon Terstappen (MCBP group), for the development of a new Raman-based methods for label-free cells analysis to distinguish subtypes of Acute Myeloid Leukemia using Raman microspectroscopy.
Currently he is Project Coordinator of “NanoPlasmiRNA“, an EU-FP7 Euronanomed II project mainly focused on the development of new Surface Plasmon Resonance Imaging based methods for the analysis of circulating biomarkers of neurodegeneration. He is author of fifteen peer reviewed articles and of several oral presentations at international conferences.
Email: email@example.comRenzo Vanna,
Silvia Picciolini graduated in pharmaceutical chemistry and technologies (CTF) at the University of Milan on March 2014. She spent one year at the Don Gnocchi Foundation doing research experience for her experimental thesis; the aim of her work was the optimization of nanohole arrays as solid SERS substrates for the detection of genetic biomarkers of acute myeloid leukemia (AML), in order to evaluate the minimal residual disease. She worked on this project in collaboration with a spin off of the Joint Research Centre (Ispra). In 2015, her research activity, funded by Compagnia Assicurativa AXA, was mainly focused on the development of a method based on Raman Spectroscopy for the detection of plasmatic biomarkers of Alzheimer’s disease. Now she is a PhD student in Translational and Molecular Medicine.
She is co-author of articles and publications appeared as poster presentations or as oral talks.
Alice Gualerzi received her Master’s degree in Biology applied to biomedical research in 2009 and her PhD degree in Morphological Sciences in 2013 at the University of Milan, focusing her research on the morphological analysis of skin and oral mucosa after exposure to exogenous stimuli in a 3D culture model. In 2012 she collaborated for six months as Junior Research Specialist with Dr. Chia-Ling Tu at the Endocrinology Unit of the VA Medical Center affiliated with the University of California San Francisco and she was later granted with a postdoctoral scholarship funded by Sardegna Ricerche to work at BT (Biomedical Tissues) srl c/o Parco scientifico e tecnologico Polaris (Pula, CA) in the field of cardiovascular tissue engineering, regenerative medicine, and nanotoxicity. In 2014 she joined LABION working on one of the main research projects of the lab about the comparative histological and Raman analysis of skin tumors. In this field, she was granted with a 12-months post-doctoral fellowship by Fondazione Umberto Veronesi in 2015.
Currently, Dr. Gualerzi is involved in two projects supported by Italian Ministry of Health aimed at the Raman characterization of extracellular vesicles from cell cultures and human biofluids to be used for tissue regeneration and diagnosis of neurodegenerative diseases.
She is author of ten papers published in peer-reviewed scientific journals and of several abstracts for national and international congresses.
Dora Mehn received her MSc in 1997 (Biology and Chemistry) and PhD in 2002 (Environmental Chemistry) after a specialization in environmental science (1999). She has been working on nanoparticle and carbon nanotube synthesis (2002-2005) at the Szeged University, Hungary and at the FUNDP, Belgium. She was head of the screening laboratory (2005-2008) at Solvo Biotechnology working also on in vitro drug interaction test and cholorimetric kit development. She spent 3 years (2008-2011) as grant-holder at the Joint Research Centre of the European Commission working on microfabrication, neuronal stem cell microarrays and nanotoxicology.
At her recent job, as senior researcher at Don Gnocchi Foundation, she acquired experience in SERS, especially in the detection of genetic biomarkers using solid SERS-enhancer surfaces. She is a co-author of 51 articles on various topics. She is co-author of 2 patents and has strong experience in translational research including the development of commercialized analytical products.
Dora Mehn left Don Gnocchi Foundation, she is currently working at Joint Research Centre (JRC).